Q-omics provides the consensus-scored KRT6B profile across patient tissues and cancer cell-line models. KRT6B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KRT6B is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, KRT6B protein abundance shows 15,704 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, COAD, and HNSC as cancer lineages where KRT6B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT6B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT6B survival associations across molecular data types. KRT6B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT6B RNA expression–survival associations across cancer types. High KRT6B expression shows unfavorable associations in KIRC, LUAD, ACC, SKCM, BLCA and PCPG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KRT6B RNA expression.
This table summarizes KRT6B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KRT6B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT6B shows lower tumor expression in BRCA and higher tumor expression in COAD, LUSC, HNSC, LUAD and CHOL. The COAD box plot shows higher KRT6B RNA expression in tumor versus normal tissue (log2 FC = +3.238, t-test p < 0.001).
This table shows molecular features associated with KRT6B in patient tissues and cancer cell lines. In patient samples, KRT6B shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT6B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
